Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia
Posted inCardiology Internal Medicine news

Oral Magnesium Reduces Risk of Death and Hospitalization in Heart Failure Patients with Hypomagnesemia

A large-scale study of US veterans demonstrates that oral magnesium therapy significantly improves outcomes in heart failure patients with hypomagnesemia, especially those with levels below 1.3 mg/dL. Conversely, supplementation in normomagnesemic patients may increase risks, highlighting the necessity of baseline-guided clinical intervention.
Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS
Posted inCardiology Internal Medicine news

Guided Antiplatelet De-escalation Proves Safe in High Atherothrombotic Risk ACS Patients: Insights from TROPICAL-ACS

Post-hoc analysis of the TROPICAL-ACS trial demonstrates that platelet function testing-guided de-escalation of dual antiplatelet therapy from prasugrel to clopidogrel is safe and effective in ACS patients, regardless of their atherothrombotic risk profile, offering a viable strategy for individualized care.
Beyond the Lungs: How Ambient Air Pollution Drives Alzheimer’s Neuropathology and Cognitive Decline
Posted inNeurology news Public Health

Beyond the Lungs: How Ambient Air Pollution Drives Alzheimer’s Neuropathology and Cognitive Decline

Emerging evidence confirms that air pollution, particularly PM2.5 and NO2, is directly associated with Alzheimer’s neuropathology, structural brain changes, and cognitive decline. New research highlights that these effects are partially mediated by pulmonary function and manifest as increased amyloid-related pathology at autopsy.
Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution
Posted inInfectious Diseases Internal Medicine news

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.
Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT
Posted inDiabetes & Endocrinology Internal Medicine news

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT

The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves' hyperthyroidism, suggesting no clinical benefit for routine supplementation.
Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）
Posted inCardiology Diabetes & Endocrinology news

Obesity as a Chronic Condition: Weight Regain Following Tirzepatide Withdrawal Reverses Vital Cardiometabolic Gains （SURMOUNT-4 trail）

A post hoc analysis of the SURMOUNT-4 trial reveals that withdrawing tirzepatide leads to significant weight regain and a proportional reversal of improvements in blood pressure, glycemic control, and lipid profiles, reinforcing the necessity for long-term obesity management.